Researchers Identify First Suite of Human Antibodies Against Measles Virus

Why It Matters

The discovery provides a tangible pathway to develop the first approved measles treatment, addressing a critical gap for immunocompromised, pregnant, and infant patients who cannot receive the vaccine.

Key Takeaways

• NIH team isolated >100 human monoclonal antibodies against measles virus
• Structural maps reveal nine distinct epitopes on H and F proteins
• Antibody 4F09 locked F protein, clearing virus from rat lungs
• Targeted sites are conserved across global measles strains, limiting escape

Pulse Analysis

Measles cases have surged worldwide, with over 470,000 infections reported in 2024 and dozens of U.S. outbreaks this year. While the MMR vaccine remains highly effective, vulnerable groups—infants, pregnant women, and immunocompromised patients—lack any approved therapeutic option. The NIH‑funded effort led by Dr. Erica Ollmann Saphire therefore fills a critical gap, delivering the first comprehensive catalog of human antibodies that can neutralize the virus. This breakthrough sets the stage for antibody‑based medicines that could protect those who cannot be vaccinated.

The researchers isolated memory B cells from a triple‑vaccinated donor and engineered more than one hundred monoclonal antibodies. Using cryo‑electron microscopy they produced atomic‑resolution maps of each antibody bound to the measles hemagglutinin (H) and fusion (F) surface proteins, identifying nine distinct epitopes. Contrary to the long‑standing belief that protection hinges mainly on H‑targeting antibodies, the study shows that F‑directed antibodies can be equally, if not more, potent. The lead candidate, 4F09, locked the F protein in its pre‑fusion state, eradicating detectable virus in rat lungs.

Because the identified epitopes are conserved across virtually all circulating measles strains, the antibodies are unlikely to be evaded by viral mutation, a key advantage for drug development. Companies can now pursue monoclonal antibody therapeutics for both post‑exposure prophylaxis and treatment of active infection, potentially shortening hospital stays and reducing mortality among high‑risk patients. The next phase will require partnership with biotech firms to scale production, conduct safety trials, and navigate FDA approval, but the scientific foundation is now firmly in place.